Pharmaceuticals Archives

NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » Pharmaceuticals

SpringWorks secures FDA approval of Ogsiveo to treat desmoid tumours

By NS Healthcare Staff Writer

28 Nov 23

The FDA approval is based on positive data from the Phase 3 DeFi trial, in which Ogsiveo significantly…

PharmaceuticalsRegulation

SpringWorks secures FDA approval of Ogsiveo to treat desmoid tumours

Arcturus secures FDA orphan drug designation for ARCT-032 in cystic fibrosis

By NS Healthcare Staff Writer

28 Nov 23

ARCT-032 has been designed to use the firm’s LUNAR lipid-mediated aerosolised platform to provide CFTR messenger RNA to…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Regeneron, Sanofi’s Dupixent reduces COPD exacerbations in second Phase 3 trial

By NS Healthcare Staff Writer

28 Nov 23

In the trial, Dupixent reduced moderate or severe acute COPD exacerbations by 34% over 52 weeks and led…

PharmaceuticalsClinical trials

GSK’s Blenrep meets primary endpoint in Phase 3 multiple myeloma trial

By NS Healthcare Staff Writer

28 Nov 23

The drug achieved the primary endpoint of progression-free survival and extended the time to disease progression or death…

PharmaceuticalsClinical trials

Boehringer Ingelheim, IBM partner to expedite antibody discovery

By NS Healthcare Staff Writer

28 Nov 23

Under the partnership, Boehringer will leverage an AI model developed by IBM, initially pre-trained and subsequently fine-tuned using…

PharmaceuticalsDrug discovery

Everest secures NMPA approval for Nefecon to treat primary IgA nephropathy

By NS Healthcare Staff Writer

27 Nov 23

Nefecon is a patented, oral delayed-release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates